CRISTIANE SANTOS DE MESQUITA
Índice h a partir de 2011
0
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
conferenceObject EGFR ACTIVATING MUTATIONS IN NSCLC: IMPORTANCE OF ROUTINE TESTING(2012) TAKAHASHI, Tiago K.; SOARES, Ibere C.; MARINI, Andrea M.; MAK, Milena P.; TEIXEIRA, Carlos H.; ROITBERG, Felipe S. R.; TAKAGAKI, Teresa Y.; MARTINS, Renata E.; MESQUITA, Cristiane; HOFF, Paulo M. G.; CASTRO JR., GilbertoBackground: EGFR activating mutations in NSCLC confer better prognosis and are also predictive of response to both chemotherapy and EGFR-tyrosine kinase inhibitors. Therefore, EGFR genotyping in NSCLC patients (pts) is very helpful in treatment decision. Here we report the first 25 pts whose tumors samples were tested for EGFR activating mutations in our Institution. Methods: It is an observational study on all consecutively tested NSCLC samples from pts treated at ICESP. Briefly, all samples were formalin-fixed and paraffin-embedded. Tumor areas were selected and macrodissected, followed by whole DNA extraction and amplification by PCR. DNA sequencing (exons 18, 19, 20 and 21) was performed by Sanger´s methodology. Frequencies were compared by Fisher´s exact test. Results and Conclusion: Results: 25 tumor samples were tested from Aug/2011 up to now: 20 pts were caucasian, 13 were male, 14 ex-smoker, 10 never smoker; 15 pts ECOG-PS 0-1 and 5 PS 2. Regarding histologic subtype, 22 were classified as adenocarcinoma and 2 SCC. Staging: 3 IIIA, 2 IIIB and 20 IV. Activating mutations were detected in 6 pts (24%): 4 in exon 19 (del 19), 1 in exon 21 (L858R) and in 1 pt two mutations were found (T790M and L858R). The frequency of these activating mutations was not related to gender (p=0.378), race (p=0.540) or smoking habits (p=0.350). In a short follow-up of 6 mo., no deaths occurred in pts whose samples were positive for activating mutations. Conclusions: In this very selected population, the frequency of EGFR activating mutations was 24%, with no correlation with gender, race or smoking habits. This reinforces the importance of testing EGFR activating mutations in all pts with lung adenocarcinoma. Disclosure: No significant relationships.conferenceObject LOCALLY ADVANCED THYMIC MALIGNANCIES TREATED WITH MULTIMODAL THERAPIES: AN OBSERVATIONAL STUDY(2014) BITTON, Rafael Caparica; LAURICELLA, Leticia; NABUCO, Pedro; SOUZA, Rodrigo Canellas De; MESQUITA, Cristiane; TERRA, Ricardo Mingarini; CASTRO JR., Gilberto DeconferenceObject Validating ECOG Performance Status as a Prognostic Factor in Brazilian Patients with Pulmonary Adenocarcinoma(2015) BITTON, Rafael C.; LIMA, Luiz G. C. A. De; ROITBERG, Felipe S. R.; MESQUITA, Cristiane; MARTINS, Renata E.; YEN, Cheng T.; TERRA, Ricardo M.; MELLO, Evandro S.; CASTRO JR., Gilberto De